
Darolutamide Approved by FDA for Metastatic Castration-Sensitive Prostate Cancer
Updated on Tuesday, June 3, 2025, at 4:15 PM. The FDA has approved darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals Inc.) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC), according to a news release from the …